

Correction to: LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes

Yvette N. Lamb¹ · Yahiya Y. Syed¹

Published online: 6 March 2018
© Springer International Publishing AG, part of Springer Nature 2018

Correction to: BioDrugs 2018; 32 (1): 91–98.
<https://doi.org/10.1007/s40259-018-0259-4>

Page 91, abstract, lines 1–6: The following sentence, which previously read:

Subcutaneous once-daily LY2963016 insulin glargine (LY insulin glargine) [Abasaglar[®] (EU); Basaglar[®] (USA)] has been approved in the EU as a biosimilar to reference insulin glargine (Lantus[®]), and in the USA as a follow-on biologic to reference insulin glargine, for use in patients with type 1 or 2 diabetes.

should read:

Subcutaneous once-daily LY2963016 insulin glargine 100 U/mL (LY insulin glargine) [Abasaglar[®] (EU); Basaglar[®] (USA)] has been approved in the EU as a biosimilar to insulin glargine 100 U/mL (Lantus[®]) [reference insulin glargine], and in the USA as a follow-on biologic to reference insulin glargine, for use in patients with type 1 or 2 diabetes.

Pages 91–2, section 1, paragraph 1, lines 4–10: The following sentence, which previously read:

Subcutaneous once-daily insulin glargine 100 U/mL (Lantus[®]) is an established effective and well-tolerated basal insulin therapy in patients with type 1 or 2 diabetes [1]. Following the recent expiration of patents for insulin glargine, biosimilars of insulin glargine developed by other

pharmaceutical companies are beginning to enter highly regulated markets [1, 2].

should read:

Subcutaneous once-daily insulin glargine 100 U/mL (Lantus[®]) [reference insulin glargine] is an established effective and well-tolerated basal insulin therapy in patients with type 1 or 2 diabetes [1]. Following the recent expiration of patents for reference insulin glargine, biosimilars of insulin glargine developed by other pharmaceutical companies are beginning to enter highly regulated markets [1, 2].

Page 92, section 1, paragraph 2, lines 1–4: The following sentence, which previously read:

Subcutaneous once-daily LY2963016 insulin glargine (LY insulin glargine) 100 U/mL [Abasaglar[®] (EU); Basaglar[®] (USA)] is a long-acting insulin analogue that is biosimilar to reference insulin glargine 100 U/mL.

should read:

Subcutaneous once-daily LY2963016 insulin glargine 100 U/mL [Abasaglar[®] (EU); Basaglar[®] (USA)] (LY insulin glargine) is a long-acting insulin analogue that is biosimilar to reference insulin glargine.

The original article can be found online at <https://doi.org/10.1007/s40259-018-0259-4>.

✉ Yvette N. Lamb
demail@springer.com

¹ Springer, Private Bag 65901, Mairangi Bay, 0754 Auckland, New Zealand